Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07078344 · ClinicalTrials.gov registry record · Phase 2
Omega-3D: Omega-3 for Diet-Driven Health Disparities
A Phase 2 study of Cardiovascular Diseases and Omega 3 Fatty Acids, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT07078344: Recruiting Phase 2 study of Cardiovascular Diseases and Omega 3 Fatty Acids, sponsored by University of Arizona.
NCT07078344 is a Phase 2 study of Cardiovascular Diseases and Omega 3 Fatty Acids that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 200 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07078344, a Phase 2 study of Cardiovascular Diseases and Omega 3 Fatty Acids, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 supplementation differ based on genetic variation in the FADS gene cluster (specifically rs174537)? Are changes in fatty acid ratios and inflammation markers greater among individuals of African ancestry compared to those of European ancestry? Researchers will compare omega-3 supplements to a placebo in a randomized, placebo-controlled crossover study to determine whether the Omega-3 supplementation is more effective in certain genetic and ancestry groups. Participants will take omega-3 supplements or a placebo daily for a defined period, then cross over to the other intervention. They will provide blood samples for analysis of fatty acid levels and inflammatory markers, complete questionnaires, and attend scheduled study visits.
Primary Outcome
This outcome evaluates the within-subject change in circulating arachidonic acid. Measurements are collected at baseline and at the end of each 12-week treatment phase in a 36-week randomized, double-blind, placebo-controlled crossover trial.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Omega-3 Fatty Acids and Safflower Oil Placebo
- DIETARY_SUPPLEMENT Safflower Oil Placebo and Omega-3 Fatty Acids
Study Locations (2)
Arizona
- Arizona Cancer Center - Tucson
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT07078344 shows while recruiting
NCT07078344 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Omega-3 Fatty Acids and Safflower Oil Placebo is the first listed.
NCT07078344 reports a single indexed study location in Arizona, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07078344 about?
NCT07078344 is a clinical study titled "Omega-3D: Omega-3 for Diet-Driven Health Disparities". The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 s...
What is the current status of trial NCT07078344?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-31. Estimated completion is 2029-12-31.
What conditions does trial NCT07078344 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Omega 3 Fatty Acids, Heart Health Markers.
What interventions are being tested in trial NCT07078344?
The interventions under investigation include: Omega-3 Fatty Acids and Safflower Oil Placebo (DIETARY_SUPPLEMENT), Safflower Oil Placebo and Omega-3 Fatty Acids (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07078344?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07078344 being conducted?
This trial has 2 study locations across Arizona, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07078344's enrollment target sits among peer trials
200 145th of 300 higher than 146 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI